Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02335918 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
A Phase 1 study, sponsored by Celldex Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 175
- Enrollment target
NCT02335918 is a Phase 1 study that has completed, run by Celldex Therapeutics. The registered enrollment target is 175 participants.
The verdict
NCT02335918, a Phase 1 study, has completed, sponsored by Celldex Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 175 participants
- Enrollment target
Study Summary
This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and nivolumab (also known as Opdivo® , BMS-936558). Both drugs target the immune system and may act to promote anti-cancer effects.
Interventions
- DRUG Combination of varlilumab and nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2015-01 |
| Est. Completion | 2018-12-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02335918
The ClinicalTrials.gov registry entry for NCT02335918 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Combination of varlilumab and nivolumab is the first listed.
NCT02335918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02335918 about?
NCT02335918 is a clinical study titled "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors". This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and nivolumab (also known as Opdivo® , BMS-936558). Both drugs target the immune system and may act to promote anti-cancer effects.
What is the current status of trial NCT02335918?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 175 participants. The study started on 2015-01. Estimated completion is 2018-12-12.
What interventions are being tested in trial NCT02335918?
The interventions under investigation include: Combination of varlilumab and nivolumab (DRUG).
Who is sponsoring clinical trial NCT02335918?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.